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ABSTRACT
Objectives: The aims of the study were as follows: 1) to determine the applicability of vacuum-assisted core needle biopsy 
in the diagnosis and management of intraductal papillomas of the breast; 2) to define factors which increase the risk for 
underestimation of breast cancer.
Material and methods: Between 2002–2017, a total of 222 cases of intraductal papillomas were diagnosed in one center 
(201 using vacuum-assisted core-needle ultrasound-guided biopsy and 21 using stereotactic biopsy). All patients under-
went scheduled follow-up imaging.
Results: Pure papillomas were diagnosed in 158 women, whereas papillomas with atypia, in this case atypical ductal 
hyperplasia (ADH), were found in 29 subjects. In the latter group, 3 cases of invasive carcinoma and 5 cases of ductal carci-
noma in situ (DCIS) were detected using open surgical biopsy. Breast cancer underestimation in that group of patients was 
20%. Overall, ADH, whose presence increases the risk for BC by thirteen-fold as compared to other accompanying lesions, 
proved to be the most important predictive factor. Also, age, non-radical biopsy excision, and high BI-RADS ultrasound 
and mammogram scores increased the probability of malignancy. During the control follow-up, no cases of IP recurrence 
in the primary localization were observed in the group without open surgical biopsy.
Conclusions: Vacuum-assisted core needle biopsy is an efficient tool in the diagnosis and management of intraductal 
papillomas of the breast. Surgical excision is not indicated in cases when a pure intraductal papilloma, and data correlation 
between the diagnosis and the clinical presentation were confirmed. Regardless, caution is advised if residual lesions were 
left and in older populations. Open surgical biopsy should remain the standard of care in cases with atypia and discordance 
between clinical and pathology data. 
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INTRODUCTION
Intraductal papillomas (IPs) of the breast are benign 
growths originating from the epithelium of the milk duct. 
Owing to their heterogeneity and the risk for coexisting 
malignant growths, IPs are classified as B3, i.e. lesions of 
uncertain malignant potential [1]. Their incidence has been 
estimated at 2–3% among the female population, but the 
risk increases to 40–70% in case of nipple discharge [2]. 
Papillomas may develop in women between the ages of 
30 and 77 years [3], and have either central or peripheral 
presentation. 
Central papillomas are typically single lesions and de-
velop in older populations. They are localized within the 
large collective ducts and usually manifest as serous or 
serosanguinous nipple discharge [4]. The risk for develop-
ing breast cancer (BC) in women with central papillomas is 
comparable to the general population [5]. 
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Peripheral papillomas are diagnosed in approximately 
10% of the cases. They usually develop in young women and 
rarely manifest as nipple discharge. Peripheral papillomas 
present as multiple, occasionally bilateral, lesions and cor-
relate with elevated risk for developing invasive BC [4, 6].
Intraductal papillomas typically present as solid, hyper-
echogenic growths within the milk ducts, which may result 
in duct enlargement, or hyperechogenic, intracystic mural 
nodules. In extreme cases, IPs may completely obscure the 
lumen of the duct or the cyst, presenting as well-differen-
tiated, hypochogenic solid masses with smooth contours 
[3, 6]. Often, IPs present as hypervascular solid masses on 
Doppler sonography [7]. On MMG, small IPs are usually 
invisible. Larger lesions present as well-differentiated, oval 
or round soft-tissue shadows [8], accompanied by non-sus-
picious microcalcifications in 25% of the cases [9]. On MRI, IPs 
range from normal images to irregular focal lesions, highly 
echogenic after the contrast agent has been administered 
intravenously, and exhibit the so-called wash-out effect, 
which is typical for malignant lesions [8, 10].  
Histopathologic examination of core needle biopsy 
(CNB) specimens remains the gold standard for the diag-
nosis of intraductal papillomas. While the diagnosis of IPs 
at core needle biopsy is always associated with the need 
for open surgical biopsy [11–13], this is not the case for 
vacuum-assisted core needle biopsy (VAB). The possibility 
of performing the so-called therapeutic biopsy and includ-
ing the affected women in the annual ultrasound control 
program is increasingly recommended [14, 15].
Objectives
The aim of the study was to determine the applicability 
of vacuum-assisted core needle biopsy in the management 
of intraductal papillomas of the breast and to identify the 
promoting factors for the risk of underestimation of malig-
nant lesions. 
MATERIAL AND METHODS
The study group included 222 women with IPs diag-
nosed using VAB, treated by a team of surgeons and gy-
necologists from a referral center for breast cancer between 
2002–2017. The patients were selected from a group of 
women who were undergoing minimally-invasive diag-
nostic procedures due to changes in the breast. In total, 
5113 biopsies (4083 USG-guided and 1030 MMG-guided) 
were performed at the time. All patients underwent an ultra-
sound examination of the breasts, with an additional mam-
mogram if the subject was over 40 years of age (161 women). 
Between 2002–2006, VAB was performed using the Mam-
motome (ESS Johnson & Johnson) system, with 11 and 8G 
needles, whereas between 2006–2017 we used the Encor 
and Encor Enspire (Bard) system, with 10 and 7G needles. 
Tissue samples were fixed in 10% buffered formalin, and 
then sent for histopathologic evaluation to the Department 
of Pathology. 
Macroscopic evaluation of the resection margins on ul-
trasound or MMG was performed and logged in the medical 
file of each patient. In 201 cases, the diagnosis was made 
using ultrasound-guided biopsy, and in 21 women as a result 
of stereotactic biopsy. 
Retrospective analysis of lesion morphology on imag-
ing, size on MMG and USG, localization (central ≤ 3cm from 
the nipple, and peripheral > 3cm from the nipple), lesion 
multifocality, categorization according to the BI-RADS 
classification (Breast Imaging-Reporting and Data System) 
[16], and macroscopic evaluation of the resection mar-
gins, was performed. The following were also taken into 
consideration: clinical symptoms (palpable tumor, nipple 
discharge, mastalgia), results of physical examination, 
menopausal status, positive personal and family history, 
and hormone therapy (hormonal contraceptives or HRT 
for over 5 years). 
Patients with IP without atypia were followed-up after 
6 months, and then every 12 months. Open surgical biopsy 
was routinely recommended in cases with atypia or suspi-
cious clinical-pathologic correlation (38 women). 
SAS 9.4 was used for statistical analysis. Continuous 
variables were presented as mean and standard deviation 
and medians. Frequencies of the categories were calculated 
for discrete and ordinal variables. T-test or Mann-Whitney 
test were used to compare continuous variables between 
the groups, chi-square test and Fisher’s test were used to 
analyze the frequencies of discrete variables. Univariate and 
multivariate logistic regression models were used to analyze 
the correlations between potential risk factors and under-
estimation of malignant lesions. The p-value of < 0.05 was 
considered as statistically significant. 
RESULTS
As far as all VAB are concerned, the rate of diagnosed 
papillomas was 4.3%, which corresponded to the group 
of 222 women aged 22–81 years (mean: 48.2 ± 12.8). 
Post-menopausal, asymptomatic women, with negative 
personal and family history of breast cancer constituted the 
vast majority of these cases. Detailed clinical characteristics 
of the study population are presented in Table 1. 
In our study, IPs were predominantly (92.3%) single le-
sions, most often (60%) in the central localization, up to 3 cm 
from the nipple. On USG, the lesions were typically well-dif-
ferentiated, hypervascular solid masses, 11.5 ± 6.2 mm in 
size (median 10 mm). On MMG, the lesions were most of-
ten described as shadows or focal asymmetric densities, 
16.2 ± 12.2 mm in size (median 12.5 mm) (Fig. 1). The vast 
majority of the cases were classified as BI-RADS 4a on USG, 
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and only 5% presented features of highly suspicious lesions 
(BI-RADS 4c or 5) and (Fig. 2). 
Detailed histopathologic results of all VAB are presented 
in Table 2. 
Surgical intervention was performed in 38 (17.1%) 
women: 22 with ADH, 4 with radial scar, 2 with DCIS, and 
1 with LCIS. In 10 cases of IPs without atypia, open surgical 
biopsy was also performed due to non-radical nature of 
the biopsy or lack of clinical-pathological correlation. The 
profile of biopsy diagnoses and histopathology results from 
the surgical excision is presented in Figure 3. 
Notably, surgical management was abandoned in 
3 cases of IPs with atypia. In 2 cases, the patients decided 
to discontinue that course of action, and in 1 case the 
decision was made because of the accompanying colon 
cancer spread. 
In our study population, 3 (1.3%) cases of invasive carci-
noma (subtypes: ductal, lobular, and tubular) and 5 (2.2%) 
cases of DCIS were found. The risk for underestimation of BC 
in patients with atypical ductal hyperplasia at biopsy was 
20%: 8% (2/25) for invasive and 12% (3/25) for non-invasive 
carcinoma in situ. The probability of developing invasive 
carcinoma in IP patients with an intraductal tumor compo-
nent was 50%, whereas the risk for DCIS in cases with pure 
papilloma was 0.6% (1/158).
Invasive carcinomas were diagnosed in 1 asymptomatic 
patient and 2 women with palpable tumors (aged 46, 61, and 
66 years, respectively), and 2 subjects without positive fam-
ily history. The tumors were solid (1 patient) or solid-cystic 
(2 patients), 12–40 mm in size. They were visible in both 
test and were classified as BIRADS 4c at USG and BIRADS 
4 or 5 in MMG. 
No correlations between the risk for BC underestimation 
and positive personal or family history, menopausal status, 
hormone therapy, lesion localization and patient complaints 
were found. However, a correlation was detected for older 
age (p = 0.0015, OR 1.7 for every 5 years) and the presence 
Table 1. Clinical characteristics of the study population
Yes No
number
[N]
rate
 [%]
number
[N]
rate
 [%]
Positive family history of 
breast cancer 62 27.9 160 72.1
Personal history of breast 
cancer 3 1.4 219 98.6
Menopause 145 65.3 77 34.7
Hormonal therapy for > 5 years 36 16.2 186 83.8
Clinical symptoms 74 33.3 148 66.7
•	 palpable tumor 39 17.6 183 82.4
•	 nipple discharge 14 6.3 208 93.7
•	 sanguinous discharge 16 7.2 206 92.8
•	 pain complaints 14 6.3 208 93.7
•	 > 1 symptom 9 4.1 213 95.9
Peripheral localization > 3 cm 
from the nipple 89 40.1 133 59.9
Single lesion 205 92.3 17 7.6
Macroscopic assessment of 
resection margins 192 86.5 30 13.5
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Figure 1. Morphology of the intraductal papillomas on imaging
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of atypia (p = 0.003, OR 16.2). The probability of BC diag-
nosis was also significantly higher (p < 0.001) in case of IP 
diagnosis at biopsy and BI-RADS classification (4c for USG 
and 4 or 5 for MMG). Identical results were obtained from 
the multivariate analysis (Tab. 3). 
Macroscopic assessment revealed that all cases of DCIS 
and invasive carcinoma were detected after residual lesion 
biopsy. The overall risk for BC underestimation was 0% for 
the radical, and 26.7% for non-radical procedures. According 
to the Fisher’s exact test, the p-value for that parameter was 
statistically significant (< 0.001). 
In the group without surgical intervention, no cases of IP 
recurrence in the primary localization were found during the 
Table 2. The spectrum of diagnoses accompanying IP in the 
specimens from vacuum-assisted core needle biopsy
Histopathologic diagnosis number[N]
rate
[%]
intraductal papilloma without atypia 158 70.3
atypical ductal hyperplasia (ADH) 25 11.3
fibroadenoma (FA) 20* 9.0
radial scars or complex sclerosing lesions 17* 7.7
lobular carcinoma in situ (LCIS) 2 0.9
ductal carcinoma in situ (DCIS) 2 0.9
*in 1 case intraductal papilloma was accompanied by FA and ADH, and in 
1 case by ADH and radial scar 
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Figure 2. Categorization of the imaging results according to the BI-RADS classification [16] in the study population
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Figure 3. The profile for the final histopathologic diagnoses in the group after open surgical excision
126
Ginekologia Polska 2019, vol. 90, no. 3
www. journals.viamedica.pl/ginekologia_polska
follow-up control program (the control period ranged from 
12 months to 16 years, mean: 28 months). New IPs in other 
localizations or in the other breast were found in 18 women 
and were again dissected using VAB. During the follow-up, 
1 case of lobular carcinoma in situ, 1 of ductal carcinoma 
in situ, and 3 of invasive carcinomas in other localizations 
were diagnosed. 
DISCUSSION
Intraductal papillomas belong to the heterogeneous 
group of lesions of uncertain malignant potential [17], which 
frequently presents a considerable diagnostic challenge. Due 
to their morphologic similarity to malignant lesions such as 
low-grade papillary DCIS, encapsulated papillary carcinoma, 
or solid papillary carcinoma, and the accompanying atypia, 
the diagnosis of IPs at CNB is associated with a certain risk for 
BC underestimation. In their 2012 meta-analysis of 34 studies 
from 1999–2012, Wen et al., demonstrated that the prob-
ability of IPs and an accompanying malignant process was 
16.6% [18]. Therefore, until recently, open surgical biopsy 
was commonly performed to remove the lesions [19–21]. 
At present, medical advances and significant progress in 
the pathology-morphology diagnosis of the breasts, espe-
cially immunohistochemistry, allow for a more precise dif-
ferentiation between various papillary growths [22]. Owing 
to that, the current underestimation of malignant BC at CNB 
ranges from 0.4 to 4% [23, 24]. Also, due to the development 
of minimally invasive techniques, e.g. VAB, the standards of 
management have changed and the indications for surgi-
cal interventions have been distinctly limited. The method 
in question allows to obtain an almost unlimited number 
of large specimens from one puncture site, and in case of 
pure papillomas it offers an equal in quality therapeutic 
option. As far as IPs with atypia are concerned, the risk for 
underestimation at CNB remains considerable, from 13 to 
92% according to the available literature [25]. In light of the 
fact that VAB does not allow for a histological evaluation 
of the resection margins, open surgical biopsy is routinely 
recommended [14, 26, 27].
The risk for underestimation of a malignant process is 
notably smaller in case of vacuum-assisted CNB as compared 
to standard CNB, and has been estimated at 0%–2.6% [14, 28] 
versus 9–21% [15, 29] for pure IPs versus IPs with atypia [15, 29]. 
Our findings are consistent with the literature. The risk for 
BC underestimation was 0.6% at VAB. The accompanying 
atypical ductal hyperplasia, as compared to other histologi-
cal diagnoses, increased the risk for malignancy by 13-fold, 
reaching 20%. 
The role of atypical growths as the most important pre-
dictive factors for a malignant process was also emphasized 
in the meta-analysis by Wen [21], or later works by Shiino, 
Han, Kiran, Boufelli or Foley [12, 23–25, 30]. Current recom-
mendations on diagnostic-therapeutic management still 
advise radical surgical approach in IPs with atypia, regardless 
of the biopsy technique [31]. Conservative management is 
allowed in strictly selected groups of patients [14, 27].
In our study, we detected an increased risk for under-
estimation in older populations, which is consistent with 
the reports by Foley et al., Rasmussen et al., and Yu et al. 
[30, 32, 33]. Therefore, caution is advised when recommend-
ing conservative management to that group of patients. On 
the other hand, we did not prove the predictive meaning 
of the accompanying clinical symptoms such as sanguine 
nipple discharge or multifocality of the lesions, which has 
been emphasized by Han et al. [23]. Also, similarly to Ras-
mussen, we found no correlation between the volume of 
the lesions at imaging and the risk for BC underestimation, 
which has been suggested by Boufelli et al., and Yu et al. 
[25, 33]. We believe it is not the volume of the lesion but the 
evaluation of sample representativeness and the results of 
clinical-pathological correlation which play the crucial role 
in the process. In our study, insufficient resection margins 
confirmed at follow-up control imaging and benign result 
of VAB in patients with high BI-RADS classification/scores, 
USG (at least 4c) and MMG (4 or 5) notably increased the 
risk for cancer underestimation. Similar correlations were 
presented by Wen et al., and Yu et al., for IPs and by Williams 
et al., for atypia [18, 33, 34]. 
We were not able to identify morphological features of 
the lesions on imaging which might become statistically 
significant predictors of benign or malignant nature of the 
change, which is consistent with the reports of Rasmussen 
et al. [32]. 
As no IP recurrence was observed during the follow-up 
period, it seems safe to assume that VAB is an effective 
method of IPs removal. However, due to the visible tendency 
for the development of new lesions in other localizations 
and increased BC incidence [13], we are of the opinion that 
the affected women should remain in the control follow-up 
program. 
CONCLUSIONS
Vacuum-assisted core needle biopsy is an effective 
technique in the diagnosis and management of intraductal 
papillomas. Our findings, as well as the reports of other 
Table 3. Contributing factors for BC underestimation in the study 
population based on the multivariate analysis 
p-value OR
Age 0.029 1.7 (1.1, 2.9)
BI-RADS category 0.004 13.1 (2.3, 75.5)
Atypia 0.026 8.2 (1.3, 52.5)
127
Diana Hodorowicz-Zaniewska et al., Underestimation of breast cancer in intraductal papillomas treated with vacuum-assisted core needle biopsy
www. journals.viamedica.pl/ginekologia_polska
authors, indicate that the diagnosis of pure papilloma and 
corresponding clinical presentation do not require further 
surgical intervention. That said, caution and careful moni-
toring are advised in older populations and cases with re-
sidual lesions. Radical surgical biopsy should remain the 
method of choice for all cases of IPs with atypia and lack of 
clinical-pathological correlation.  
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